Recombinant Human ECM1 protein (His Tag)

ED50

/

Species

Human

Purity

>95 %, SDS-PAGE

GeneID

1893

Accession

AAH23505

Cat No : Eg0533

Print datasheet

Synonyms

ECM1,extracellular matrix protein 1,Secretory comp



Technical Specifications

Purity >95 %, SDS-PAGE
Endotoxin Level <1.0 EU/μg protein, LAL method
Biological Activity
Not tested
Source HEK293-derived Human ECM1 protein Ala20-Glu540 (Accession# AAH23505) with a His tag at the C-terminus.
Predicted Molecular Mass 63 kDa
SDS-PAGE 68-90 kDa, reducing (R) conditions
Formulation Lyophilized from sterile PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization.
Reconstitution Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water.
Storage
It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
  • Until expiry date, -20℃ to -80℃ as lyophilized proteins.
  • 3 months, -20℃ to -80℃ under sterile conditions after reconstitution.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature.

Background

ECM1 (extracellular matrix protein 1), also known as URBWD. It is located in secreted, extracellular space, and extracellular matrix, which is mainly expressed in esophagus and gall bladder. The gene encodes a soluble protein that is involved in endochondral bone formation, angiogenesis, and tumor biology. It also interacts with a variety of extracellular and structural proteins, contributing to the maintenance of skin integrity and homeostasis. Mutations in this gene are associated with lipoid proteinosis disorder (also known as hyalinosis cutis et mucosae or Urbach-Wiethe disease) that is characterized by generalized thickening of skin, mucosae and certain viscera. The calculated molecular weight of ECM1 is 60 kDa, and this antibody can recognize the 63 kDa isoform of target, moreover, this protein may have glycosylation modification.

References:

1. Chen H. et al. (2010). Med Oncol. 1:S318-25. 2. López-Marure R. et al. (2011). Eur J Pharmacol. 660(2-3):268-74. 3. Lee KM. et al. (2015). Oncogene. 34(50):6055-65.